European biotech VC Forbion closes two funds at $1.5B total in its biggest raises to date
European life sciences venture capital firm Forbion has closed two of its funds — one early-stage and one late-stage — at €750 million (about $823 million USD) and €600 million ($658 million USD) respectively, it announced Wednesday morning.
Forbion initially closed its late-stage fund in June at €470 million before reaching the hard cap on the fund at €600 million. Known as the Forbion Growth Opportunities Fund, the raise was Forbion’s second late-stage specific fund. With the money, Forbion plans to invest up to €70 million per deal, and Forbion managing partner and co-founder Sander Slootweg said the firm plans to invest in 12 to 15 companies via that fund.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
